Psoriasis is a chronic inflammatory skin condition, with genetic, epigenetic, environmental, and lifestyle factors contributing to its onset and recurrence. Severe psoriasis has a great impact on quality of life, which is similar to that of insulin-dependent diabetes, depression, and ischemic heart disease, but with a lower mortality. There is an overlap between the rising incidences of autoimmune diseases and obesity. In recent years, research has shown that there is an association between psoriasis and obesity. Psoriasis is linked to obesity in a two-way manner, as each can precipitate the development of the other. Several adipose tissue-secreted adipokines were shown to be elevated in obese psoriasis patients, exhibiting similar mechanisms of action to those underlying the pathogenesis of psoriasis. Excess body weight can influence not only the treatment response in psoriasis, but also the adverse events, leading to decreased patient compliance. Specific human microbiome patterns have been identified for obesity and psoriasis and could represent a future therapeutic target in selected individuals.

The European Society for Medical Oncology experts have identified the main components of the long-term management of oncological patients. These include early diagnosis through population screening and periodic control of already diagnosed patients to identify relapses, recurrences, and other associated neoplasms. There are no generally accepted international guidelines for the long-term monitoring of patients with skin neoplasms (nonmelanoma skin cancer, malignant melanoma, precancerous—high-risk skin lesions). Still, depending on the experience of the attending physician and based on the data from the literature, one can establish monitoring intervals to supervise these high-risk population groups, educate the patient and monitor the general population.

Background/Objectives: Alcohol use disorder (AUD) contributes substantially to premature mortality and disability in Romania. Recovery is commonly evaluated according to abstinence status, with less attention to psychological functioning, social support, spiritual well-being, and quality of life. SER-ABS-AUD (ClinicalTrials.gov identifier NCT07561749) examines ‘serene abstinence’ as a preliminary multidimensional recovery construct among adults with AUD receiving community-based recovery support. Methods: This single-center, non-interventional, mixed retrospective–prospective longitudinal cohort study aims to enroll 70 adults aged 18–70 years with documented AUD, at least 12 consecutive months of continuous alcohol abstinence before enrollment, and an archived pre-enrollment MCMI-IV profile. Following written informed consent at the current T2 study visit, archived T1 MCMI-IV data and available clinical information will be extracted, and the MCMI-IV and supplementary recovery-outcome battery will be administered prospectively at T2. The principal longitudinal outcome is within-person change in prespecified MCMI-IV scales between archived T1 and current T2 assessment. The secondary exploratory Serene Abstinence Index combines MCMI-IV persistent depression change with current T2 natural reward response, spiritual well-being, and quality of life. Supplementary T2 measures will be interpreted as current outcomes or concurrent exploratory correlates, not as repeated longitudinal measures. Results: Recruitment is ongoing; no participant-level outcome data are reported in this protocol. Conclusions: SER-ABS-AUD will estimate longitudinal MCMI-IV change and characterize multidimensional recovery in a Romanian community-based AUD setting. Findings will be hypothesis-generating and will require replication and external validation in larger, independent, multicentre cohorts.